Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Key Highlights
- ➤Valion Bio (VBIO) completes initial BioScan-NMR feasibility evaluation through Velocity Bioworks
- ➤BioScan-NMR measurements strongly correlate with OD600, supporting microbial-growth tracking potential
- ➤LarmorBio is developing closed-system, continuous monitoring to detect fermentation deviations earlier
- ➤Velocity Bioworks will assess BioScan-NMR’s closed-system and continuous-monitoring capabilities next
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Innovation and differentiation are increasingly important competitive advantages in the CDMO industry, and this milestone represents what we believe is meaningful progress in our strategy to bring new, clearly differentiated technology into our bioprocessing capabilities.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We are particularly encouraged by this initial achievement and the potential for BioScan-NMR™ to further differentiate Velocity Bioworks.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“While this project remains an early-stage proof-of-concept, the initial results are encouraging,”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We believe BioScan-NMR(™) has the potential to provide greater visibility into fermentation processes, including information related to the media composition, fermenter environment, process conditions, and potentially product-related attributes - without relying solely on routine invasive sampling and sample processing. We look forward to the full implementation of this unique PAT system at Velocity Bioworks.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“The potential to move beyond episodic sampling toward continuous process visibility is particularly compelling from a CDMO perspective,”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“If subsequent development work confirms that BioScan-NMR™ can reliably monitor additional critical process attributes in a closed system, it could become an important enabling technology for more data-rich, responsive, and efficient bioprocessing.”
SAN ANTONIO, TX AND WALTHAM, MA / ACCESS Newswire / October 15, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization ("CDMO") subsidiary, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR(™) platform. * BioScan-NMR™ is being developed to create a new class of process analytical technology ("PAT") for biologics manufacturing. * The initial feasibility evaluation demonstrated that nuclear magnetic resonance ("NMR") measurements have the potential to track microbial growth during a fermentation process. * Building on that foundation, LarmorBio is developing a real-time, continuous monitoring platform designed to:* Bring biological visibility directly into the manufacturing process, with the potential to detect deviations earlier * Reduce the risk of batch failures * Lower manufacturing costs * Enable more consistent and efficient production "Innovation and differentiation are increasingly important competitive advantages in the CDMO industry, and this milestone represents what we believe is meaningful progress in our strategy to bring new, clearly differentiated technology into our bioprocessing capabilities," said Dean Zikria, Interim Chief Executive Officer of Valion. He continues, "We are particularly encouraged by this initial achievement and the potential for BioScan-NMR™ to further differentiate Velocity Bioworks."
Get started
Create a free account to read the full story.